Why GLP-1 Drugs Work Better for Some People Than Others
A contrarian look at why GLP-1 drugs work differently, what the new genetics paper actually shows, and what patients should do with that information.
Foundayo: What Lilly’s New Weight Loss Pill Really Means
Foundayo matters, but not for the reason most headlines suggest. A weight-loss pill with meaningful efficacy is commercially important. That does not make it clinically supreme. Convenience is an advantage. It is not an argument. The harder question remains the old one: what happens after the initial appetite suppression has done its work?
Retatrutide Phase 3 Diabetes Results: What They Actually Show
Retatrutide’s phase 3 diabetes results are impressive. That is not the same thing as saying the matter is settled. Strong A1C reduction, serious weight loss, familiar gastrointestinal trade-offs, and still only top-line data. Medicine should resist intoxication by headlines.